Koninklijke Philips N.V. (NYSE:PHG) Q2 2024 Earnings Conference Call July 29, 2024 4:00 AM ET
Company Participants
Leandro Mazzoni - Head of Investor Relations
Roy Jakobs - Chief Executive Officer
Abhijit Bhattacharya - Chief Financial Officer
Conference Call Participants
Hassan Al-Wakeel - Barclays
Richard Felton - Goldman Sachs
David Adlington - JPMorgan
Veronika Dubajova - Citi
Hugo Solvet - Exane BNP Paribas
Julien Ouaddour - Bank of America
Robert Davies - Morgan Stanley
Sezgi Ozener - HSBC
Falko Friedrichs - Deutsche Bank
Ed Ridley-Day - Redburn
Operator
Welcome to the Royal Philips Second Quarter and Semiannual 2024 Results Conference Call on Monday, July 29, 2024. During the call hosted by Mr. Roy Jakobs, CEO; and Mr. Abhijit Bhattacharya, CFO, all participants will be in a listen-only mode. [Operator Instructions] Please note that this call will be recorded and replay will be available on the Investor Relations website of Royal Philips.
I'll now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir.
Leandro Mazzoni
Hi, everyone. Welcome to Philips' second quarter and half year 2024 results webcast. I'm here with our CEO, Roy Jakobs and our CFO, Abhijit Bhattacharya. The press release and investor deck were published on our Investor Relations website this morning. The replay and full transcript of this webcast will be made available on the website after the call as well. Before we start, I want to draw your attention to our Safe Harbor statement on screen. You will also find the statement in the presentation published on our Investor Relations website.
Roy, over to you.
Roy Jakobs
Good morning, everyone and welcome. Great to be with you today. I want to start with the key highlights of this morning's release. We delivered strong order intake growth this quarter. Within a challenging macroeconomic environment, we achieved strong margin improvement supported by our productivity program, solid operational cash flow and comparable sales growth in line with our plan.
The improvements were across all business segments and a result of the ongoing actions to enhance execution, supported by our innovations. We continue to make progress and see the effects of the focus on our 3 priorities: enhancing patient safety and quality; strengthening our supply chain reliability; and establishing a simplified, more agile operating model. Supported by key innovation launches and our ongoing actions, we are confident in our plan and reiterate our outlook for the full year 2024.